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Abstract: Multiple myeloma (MM) belongs to hematological cancers and its incidence is increasing
worldwide. Despite recent advances in its therapy, MM still causes many deaths every year. In fact,
current therapies sometimes fail and are associated with severe adverse effects, including neurotoxicity.
As a part of our ongoing efforts to discover new potential therapies against MM, we prepared Hibiscus
sabdariffa extracts obtained by a microwave-assisted solvent extraction and investigate their activity by
in vitro assays on the RPMI-8226 cell line. The bioguided fractionation of the crude ethanolic extract
allowed the identification of HsFC as the most effective extract. We assessed cell viability (MTT and
Tripan blue test), cell migration (Boyden chamber assay), and neurotoxicity (DRG neurotoxicity assay).
The promising results prompted us to further fractionate HsFC and we obtained two molecules
effective against RPMI-8226 cells without neurotoxic effects at their active concentrations. Moreover,
both compounds are able to significantly reduce cell migration.
Keywords: Multiple myeloma; Hibiscus sabdariffa; nature-aided drug discovery; bioguided assay
fractionation; Hib-ester; Hib-carbaldehyde
1. Introduction
Multiple myeloma (MM) is a plasma cell neoplastic disorder causing severe bone pain and
bone fractures, hypercalcemia, anemia, and kidney damage. This disease is characterized by clonal
proliferation of malignant plasma cells in bone marrow and by overproduction of monoclonal protein
(M protein) [1]. MM represents 1% of all cancer diseases and 10% of hematological cancers and its
incidence is highly variable among age, sex, and countries [2]. MM is prevalent among the elderly
and the male sex and the most affected countries are the industrialized regions of Australia, Europe,
and North America. MM is still considered an incurable disease causing 110,000 deaths every year
worldwide. To date, different therapeutic options are available and over the last decade, the five-year
relative survival of patients raised approximately to 56% [3]. Nevertheless, the high heterogeneity
of MM leads to numerous cases of refractory/relapsing MM. Moreover, since bone marrow is the
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ideal support for homing and progression of MM cells [4], 70% of patients presents bones metastasis
at diagnosis and the percentage further increases to 90% during the development of the disease.
These patients suffer from osteolytic lesions caused by osteoblast differentiation suppression and
inhibition of bone matrix deposition [5]. Therefore, MM still represents an unmet medical need.
During the last five years, new targets in MM have been proposed as therapeutic options (Figure 1),
thus broadening the MM therapeutic landscape. Several drugs are now available and new molecules
have recently been approved (Table 1) other therapies, including a peptide-based vaccination, are under
validation [6]. Briefly, the main MM therapies consist of:
• DNA damaging agents. Alkylating agents such as melphalan and other DNA damaging agents
such as doxorubicin as well as pan-HDAC inhibitors such as panobinostat are still important
MM drugs [7].
• Proteasome inhibitors [8]. The proteasome is a multicatalytic target responsible for the degradation
of 80–90% of proteins during cell life. Until now, three proteasome inhibitors have been approved
for clinical use: Bortezomib, Carfilzomib, and Ixazomib. Particularly, Bortezomib was the first
FDA-approved proteasome inhibitor and represents one of the most important discoveries for
fighting MM of recent years. Of note, these agents can stimulate bone formation in MM patients [9].
Proteasome modulation can be also achieved by employing small molecules such as lenalidomide,
structurally related to thalidomide and acting as E3-Ligasi inhibitors [10].
• Immunomodulators [11]. MM was among the first tumors wherein the therapeutic efficacy
of blockade of inhibitory immune receptors, particularly the PD-1 axis, was demonstrated in
preclinical models.
• Monoclonal antibodies [12]. There are only two FDA-approved monoclonal antibodies for the
treatment of MM: daratumumab, targeting the CD38 pathway, and elotuzumab, targeting the
SLAMF7 pathway. Despite the efficacy of this strategy in long term cancer remission, monoclonal
antibodies still remain very expensive, thus limiting their diffusion.
It has to be pointed out that treatments currently available are often unsuccessful, lead to
drug resistance [13], and cause adverse effects [14]. One of the major side effects related to MM
therapies is a dose-limiting neurotoxicity, often linked to chemotherapy-induced peripheral neuropathy,
which generally presents several sensory symptoms, including hypersensitivity, dysesthesia,
and paresthesia [15,16]. At least 60% of patients treated with Bortezomib shows this severe side effect,
leading to dose reduction or complete suspension of the therapy.
Therefore, despite the efforts of the scientific community, MM therapy is still considered an unmet
medical need and new effective therapies are needed.
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Table 1. Drugs approved for multiple myeloma and their molecular targets.
Drug Trade Name Target
Melphalan Alkeran® DNA
Bendamustine Levact®, Ribomustin®, Treanda® DNA
Doxorubicin Adriamycin® DNA
Carmustine BiCNU® DNA
Cyclophosphamide Cytoxan®, Neosar® DNA
Panobinostat Faridak® HDAC
Elotuzumab Empliciti® CS1
Daratumumab Darzalex® CD38
Bortezomib Velcade® Proteasome
Ixazomib Ninlaro® Proteasome
Carfilzomib Kyprolis® Proteasome
Thalidomide Thalidomide Celgene® E3 ligase
Lenalidomide Revlimid® E3 ligase
Pomalidomide Imnovid® E3 ligase
Our research group has been studying MM from a pharmacological point of view for several
years [17–19] and only recently we have focused on the identification of new therapeutic opportunities.
Following a nature-aided drug discovery approach, we demonstrated the beneficial effects of Hibiscus
sabdariffa Linn against MM [20]. H. sabdariffa is an annual herbaceous subshrub belonging to the
Malvaceae family that is also known as Roselle, Red Sorrel or Karkadè. This plant is commonly
distributed in tropical and subtropical regions and it is originally native to India and Saudi Arabia.
It is cultivated in different regions such as Sudan, Egypt, Nigeria, Mexico, Saudi Arabia, Taiwan,
West Indies, Central America, and European countries [21–23]. H. sabdariffa calyces are commonly used
for the preparation of tea and infusions. The red drink is widely consumed directly or it is an ingredient
in the preparation of some foods, such as juice, jam, pudding, gelatin, and desserts [24]. Moreover,
it is well known in traditional medicine for its diuretic and mild laxative effects. Along the years,
the phytochemical composition H. sabdariffa calyces as well as their pharmacological properties have
been extensively studied. Different H. sabdariffa extracts have been prepared and the main constituents
are phenols, polyphenols, anthocyanins, and organic acids, such as citric, tartaric, malic, ascorbic acids,
and others [24,25]. Several studies demonstrated that H. sabdariffa calyces possess high antioxidant
and anti-inflammatory properties and are able to counteract hypertension [26], diabetic status [27],
microbial infections [28], as well as to slow down the development of atherosclerosis [29].
H. sabdariffa is known to possess antiproliferative properties and to be a possible source of new
bioactive compounds for cancer treatment; it shows an antiproliferative effect against MCF-7 and
MDA-MB-231 breast carcinoma cells, CaoV-3 ovarian cancer cells, Hela cervical cancer cells, and K-562
leukemia cells [30–33]. Moreover, anthocyanins extracted from H. sabdariffa are able to induce apoptosis
of promyelocytic leukemia HL-60 cells via the p38 MAP kinase pathway [34].
To continue the study on the anticancer potential of H. sabdariffa calyces, specially focusing on
MM, in this work we focused on the preparation and bioassay-guided fractionation of its ethanolic
extract. Herein we report the isolation, structure elucidation, and evaluation of the potential of
Hibiscus acid dimethyl ester and of a new aldehydic compound against multiple myeloma. In detail,
their cytotoxicity and effect on cell migration and invasion of RPMI-8226 MM cells as well as their
neurotoxicity on embryo rats dorsal root were evaluated.
2. Results and discussion
The dried and powdered H. sabdariffa calyces were extracted following a microwave-assisted
solvent extraction (MASE) procedure exploiting 80% ethanol as the extracting solvent [35–38].
The obtained ethanolic extract (HsEE) was then fractionated via a liquid/liquid extraction, suspending
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the extract in water and sequentially extracting with hexane (A), dichloromethane (B), ethyl acetate (C),
and butanol (D), yielding four organic fractions (HsFA–D) and an aqueous one.
To obtain the analytical fingerprint, useful both as a control of the extracts’ quality and as a starting
point for future purification studies, we set up a proper RP-HPLC-UV/PAD-ESI/MS method [39].
Specifically, different elution conditions (methanol, acetonitrile, water, with or without formic acid)
adopting several gradient modes were tested on two different columns (Symmetry C18 and Chromolith
Performance RP-18 endcapped). The best results in terms of peak resolution, peak shape, and time
of analysis were achieved using a Symmetry C18 (5 µm, 3.9 × 150 mm) column in gradient elution
conditions, using water and ACN added with formic acid. The HsEE HPLC-UV chromatograms
(λ = 325 nm) together with the reconstructed ion chromatograms (RIC) in negative ion mode are shown
in Figure 2.
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Figure 2. HPLC-UV/PAD-ESI/MS profile recorded at λ = 325 nm (black line) and reconstructed ion
chromatograms (red line) of H. sabdariffa ethanolic extract (HsEE).
With the HPLC-UV-ESI/MS analytical methodology in hands, the profiles of fractions A–D were
drawn: HsFA and HsFB contain only compounds with low polarity (retention time >12 min), HsFC
presents acidic components (hibiscus acid, 5-caffeoylquinic acid and isomers, caffeic acid), while HsFD
shows only few peaks at low intensity. The chromatographic profiles of HsFA–D and the MS associated
with the peaks (total ion content) are reported in the Supplementary Material (Figure S1, Table S1).
In the meantime, the effect of HsEE and HsFA-D on cell viability of RPMI 8226 cells was assessed
by MTT vital count assay. Cells were treated with different concentrations of HsEE (1–50 mg/mL)
or HsFA-D (1–10 mg/mL) for 24, 48, and 72 h. Untreated cells were used as control.
HsEE and HsFC are able to impair cell viability of RPMI 8226 cells in a dose- and time-dependent
manner with IC50 at 24 h of 21.3 mg/mL and 3.5 mg/mL for HsEE and HsFC, respectively (Figure 3).
The other fractions were not active and therefore were discarded (data not shown).
The in vitro neurotoxicity of the crude extract, HsEE, and of the most effective fraction, HsFC,
was then assessed by the well consolidated embryo rats dorsal root ganglia (DRG) neurotoxicity
model [40]. Briefly, DRG explants from E15 Sprague Dawley rat embryos are able to sprout neurites
when cultured with prodifferentiation agents, and the neurite outgrowth is blocked or slowed by
neurotoxic agents. DRG were treated with different concentrations of HsEE (1–50 mg/mL) or HsFC
(1–10 mg/mL) for 24 and 48 h and then the neurite outgrowth was measured. Results showed that HsEE
and HsFC are non-neurotoxic at doses lower than 7.5 mg/mL and 3 mg/mL, respectively, after both
24 h and 48 h of treatment (Figure 4). At these time points, neurotoxicity was evident for both extracts
at higher concentrations. HsEE is highly neurotoxic at its active concentrations (IC50 = 21.3 mg/mL),
while HsFC can be considered safe at concentrations near its IC50 (IC50 = 3.5 mg/mL).
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Figure 3. RPMI 8226 cell viability after HsEE or HsFC treatment. (A) MTT assay of RPMI 8226 cells
treated with different concentrations (1–50 mg/mL) of HsEE for 24, 48, and 72 h. (B) MTT assay of
RPMI 8226 cells treated with different concentrations (1–10 mg/mL) of HsFC for 24, 48, and 72 h.
Untreated cells (CTRL) are control. Graphs represent the mean percentage ± SD of viable cells of three
independent experiments (* p < 0.05, ** p < 0.01 vs. CTRL).
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Figure 4. In vitro DRG neurotoxicity of HsEE and HsFC. (A) Neurite outgrowth from DRG treated
with HsEE for 24 and 48 h. (B) Neurite outgrowth from DRG treated with HsFC for 24 and 48 h.
Graphs represent mean neurite length ± SD of three independent experiments. (** p < 0.01 vs. CTRL).
(C) Representative images of DRG treated with HsEE or HsFC for 24 and 48 h. Untreated DRG represent
the controls.
We decided to further investigate HsFC at the effective and non-neurotoxic concentration of
3 mg/mL, evaluating the cell viability/cell death (RPMI 8226 cells) by Trypan blue vital count assay and
the cell migration and invasion properties by Boyden chamber assay.
Results of Trypan blue assay after treatment of RPMI 8226 cells with HsFC (3 mg/mL for 24, 48
and 72 h) highlighted that this fraction reduced cell viability and increased the number of dead cells
from 8% (of untreated cells) to 20% (at 24 h), 43% (at 48 h), and 61% (at 72 h) (Figure 5). Moreover,
the replacing of the culture medium after 24 h of treatment with fresh medium without HsFC generated
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a growing curve comparable to that obtained with continuous treatment; therefore, the HsFC effect is
not reversible. (Figure 6). Regarding the cell migration and invasion, assessed by Boyden chamber
assay, the treatment with HsFC significantly inhibited the ability of untreated RPMI 8226 cells in the
presence of FBS as chemoattractant to pass through the gelatin-coated membrane. The HsFC effect was
similar to that observed when untreated RPMI 8226 cells are in the absence of the chemoattractant FBS
(Figure 7). Seventy percent of patients presents bone metastasis at diagnosis of MM and the percentage
further increases during the development of the disease and can reach 90% of patients. For these
reasons, it is important to identify drugs that are not only toxic to MM but that are also effective against
MM bone metastasis formation.
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Figure 6. Effect of RPMI 8226 cells treated with HsFC 3 mg/mL in continuous (cont) or in washout (wo)
culture medium. (A) Time schedule of HsFC treatment. Black arrows represent the presence of HsFC
in culture medium of cont or wo treatment. Dashed lines represent culture medium without treatment.
(B) Graphs represent the mean ± SD number of viable cells counted in three independent experiments.
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Figure 7. RPMI 8226 cell migration/invasion after HsFC treatment. The migration/invasion ability
of RPMI 8226 cells was assessed by Boyden chamber assay. Cells were treated with HsFC 3 mg/mL.
Untreated cells with or without FBS as chemoattractant represent positive controls (CTRL pos) and
negative controls (CTRL neg), respectively. Data represent the percentage of migrating cells with
respect to CTRL pos, arbitrarily set to 100%, and are expressed as mean ± SD of three independent
experiments. (** p < 0.01 vs. CTRL pos).
To identify the main metabolites responsible for the cytotoxic properties, HsFC was then
further fractionated. A first purification with polymer-supported carbonate (PS-carbonate) of HsFC
was performed. Briefly, the fraction dissolved in methanol was treated with PS-carbonate, the
solvent removed, and the resin washed with fresh methanol and dichloromethane. The washing
solvent was collected and evaporated under reduced pressure, obtaining the wash fraction (WF).
The PS-carbonate was then treated with 0.1% HCl in methanol, thus obtaining a simplified fraction.
The subsequent purification by flash chromatography allowed the isolation of six fractions which
underwent a preliminary cytotoxicity screening (MTT test). Only one fraction was active against MM
in the initial screening. The HPLC-MS analysis showed that the white solid obtained corresponded to
a pure compound with m/z 218.
The 1H-NMR spectrum recorded in DMSO is consistent with that reported in literature for hibiscus
acid dimethylester [41]. To confirm the γ-lactonic structure of this compound, bidimensional NMR
(1H-13C HSQC J = 8 Hz, HSQC J = 2 Hz and 1H-13C HMBC) in CDCl3 was recorded (Figure S8). Basing
on this data and on the positive value of its specific optical rotatory power recorded in chloroform
and acetonitrile ([α]D20 = + 57.0 and + 84,1, respectively), the compound has been identified as
(2S,3R)-hibiscus acid dimethylester (Figure 8A), by now on called Hib-ester [41].
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It has to be noted that, according to the purification procedure, PS-carbonate caught acid
compounds present in HsFC, including the hibiscus acid.
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Further fractionation of WF by flash chromatography yielded four main fractions, which
underwent MTT cytotoxicity screening. A yellow oil, corresponding to new pure compound
showing an interesting MTT value, was isolated. This compound was identified by NMR techniques
(1H-NMR, 1H-13C HSQC J = 8 Hz, HSQC J = 2 Hz and 1H-13C HMBC) and MS analysis (m/z 126) as
5-hydroxy-2H-pyran-6-carbaldehyde, hereafter called Hib-carbaldehyde (Figure 8B). This compound has
not been isolated from natural sources before.
The effect of Hib-ester and Hib-carbaldehyde on cell viability of RPMI 8226 cells was evaluated
by MTT and trypan blue vital count assay. Cells were treated with increasing concentrations of the
compounds (3 µg/mL–3 mg/mL) for 24, 48, and 72 h and untreated cells were used as control.
Both compounds significantly reduced cell viability of RPMI 8226 cells (MTT test) in a dose- and
time-dependent manner (Figure 9A,B). After 24 h of treatment, Hib-ester and Hib-carbaldehyde are about
ten and 20 times more active than HsFC, showing IC50 values of 0.45 and 0.21 mg/mL, respectively.
Results of the trypan blue vital count assay highlighted a similar trend (Figure 9C,D).
The evaluation of the in vitro neurotoxicity of Hib-ester and Hib-carbaldehyde using our DRG model
showed that both compounds are non-neurotoxic at doses near the IC50 values, after both 24 h and
48 h of treatment. Hib-carbaldehyde at 0.3 mg/mL and 1 mg/mL reduced the length of neurites, but at
a non-neurotoxic percentage (about 20%) (Figure S8).
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Figure 9. Cell viability and neurotoxicity after treatment with Hib-ester and Hib-carbaldehyde. (A) MTT
assay of RPMI 8226 cells treated with Hib-ester (3 µg/mL–3 mg/mL) for 24, 48, and 72 h. (B) MTT assay
of RPMI 8226 cells treated with Hib-carbaldehyde (3 µg/mL–3 mg/mL) for 24, 48, and 72 h. (C) Trypan
blue vital count assay of RPMI 8226 cells treated with Hib-ester (3 µg/mL–1 mg/mL) for 24, 48, and
72 h. D) Trypan blue vital count assay of RPMI 8226 cells treated with different concentrations of
Hib-carbaldehyde (3 µg/mL–1 mg/mL) for 24, 48, and 72 h.
Regarding the ability to impair cell migration and invasion, both compounds are effective at their
respective IC50 values. Particularly, Hib-ester inhibits cell migration and invasion by more than 50% at
30 µg/mL (Figure 10A,B).
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Figure 10. RPMI 8226 cells’ migration/invasion after Hib-ester and Hib-carbaldehyde treatment.
Migration/invasion ability of RPMI 8226 cells was assessed by Boyden chamber assay. (A) Cells
were treated with Hib-ester (3 µg/mL–1 mg/mL). (B) Cells were treated with Hib-carbaldehyde
(3 µg/mL–1 mg/mL). Data represent the percentage of migrating cells with respect to CTRL, arbitrarily
set to 100%, and are expressed as mean ± SD of three independent experiments. (** p < 0.01 vs.
CTRL pos).
3. Conclusions
In this paper, we prepared a hydroalcoholic H. sabdariffa extract by adopting a MASE-based
methodol gy, an efficient method to extract secondary metabolites from raw matrices with high yields
and in short time. Microwave oven parameters (te perature, ower, and time) were chosen according
to literature data concerning the stability of the main metabolites of H. sabdariffa [42]. The bioguided
fractionation of the crude ethanolic extract (HsEE) (sequential liquid/liquid extraction using organic
solvents with growing polarities, followed by chromat graphic fractionation) allowed the identification
of two active comp unds, named Hib-ester and Hib-carbaldehyde (Figure 8).
Both compounds are effective against the tested MM cell line at non-neurotoxic µg/mL
concentrations. re er, they are able to reduce cell migratio and invasion, eve ts involved
in the process of metastasis. Compoun s identified in this study may be the starti i t for the
antineoplastic medicinal chemistry field. We expect that our results can offer usef l information for the
identification of next-generation drugs against multiple myeloma.
4. Materials and Methods
4.1. Chemicals and Standards
Solvents for both HPLC (HPLC grade) and extraction procedures (analytical grade) were supplied
by Carlo Erba (Milan, Italy). Chlorogenic acid was purchased from Indena S.p.A. (Milan, Italy).
Analytical thin-layer chromatography (TLC) was carried out on silica gel precoated glass-backed
plates (Fluka Kieselgel 60 F254, Merck, Darmstadt, Germany) and visualized by UV light or ceric
ammonium molibdate (IV) stain (Hanessian’s Stain).
Flash chromatography was performed with silica gel 60 (particle size 230–400 mesh) purchased
from Nova Chimica (Cinisello Balsamo, Italy).
Deuterated solvent for NMR spectroscopy, RPMI-1640 Medium, Phosphate Buffered Saline (PBS),
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), di ethylsulfoxide (DMSO) were
purchased from Sigma Aldrich (Milan, Italy).
Fetal bovine serum (FBS; GibcoR) was purchased from ThermoFisher Scientific (Lisbon, Portugal).
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4.2. Instruments
H. sabdariffa calyces were powdered using a blade mill (A10 IKA-Werke GmbH & Co., Staufen,
Germany) and then extracted exploiting a Multimode Microwave apparatus (MARSX press, CEM
Corporation, Matthews, NC, USA).
All solvents were evaporated under reduced pressure using a Heidolph Laborota 4000 instrument
(Heidolph Instruments GmbH & Co., Schwabach, Germany).
1H-NMR, 13C-NMR, and bidimensional experiments were performed at 400.0 MHz and 100.6 MHz,
respectively, on the Bruker Avance 400 MHz FT NMR spectrometer (Bruker, Leipzig, Germany) with
a multinuclear BBO probe. CDCl3 was used as solvent. 1H chemical shift values were reported on the
δ scale in ppm, relative to TMS (δ = 0.0 ppm) and in 13C-NMR, chemical shift values were reported
posing CDCl3 (δ = 77.36 ppm) as reference.
High performance liquid chromatography-electrospray-tandem mass spectrometry (RP-HPLC-
UV/PAD-ESI/MS) analyses were carried out on Finnigan LCQ fleet ion trap system, controlled by
Xcalibur software 1.4 (ThermoFinnigan, San Jose, CA, USA).
4.3. Plant Material and Extraction Procedure
H. sabdariffa plants obtained from seeds were cultivated in pots under greenhouse conditions
(mean temperature 25.9 ◦C) at CREA institute (43◦49′05”N, 7◦45′30”E, Sanremo, IM, Italy).
H. sabdariffa calyces from five-month-old plants were harvested at the end of September, separated
from the seedpod, and after a rapid wash with tap water, dried in a ventilated oven at 45 ◦C for three
days. Voucher samples of dry calyces (ca. 100 g) are conserved under room conditions at the Plant
Propagation Laboratory of the CREA, Sanremo, Italy. Seeds of this HS line are also kept for regular use.
The obtained matrix was stored in dark conditions and, at the time of use, it was cut to small
size and grounded with a blade mill. Then, 10 g of the obtained homogeneous fine powder were
dispersed in 200 mL of ethanol 80% and subjected to microwave heating (2 min ramping, 5 min hold
time, maximum pressure 120 psi, maximum potency 200 W, temperature 50 ◦C, one cycle). The mixture
was left to cool at room temperature filtrated and concentrated under reduced pressure to obtain HsEE
as a red thick oil.
4.4. Extract Fractionation and Analysis
The crude extract HEE was resolubilized in water and sequentially extracted three times.
with hexane (A), dichloromethane (B), ethyl acetate (C), and butanol (D) as organic solvents.
The combined organic phases were dried with anhydrous NaSO4 and the solvent removed
under reduced pressure, yielding four organic fractions (HsFA–D) and an aqueous fraction.
All dry extracts obtained were stored at 4 ◦C until analysis. Each extraction experiment was
carried out in triplicate. HsEE and HsFA–D were analyzed using high-performance liquid
chromatography-electrospray-tandem mass spectrometry. Each sample was dissolved in water
(4 mg/mL) and filtered with a 0.45 µm GH Polypro (GHP) membrane before injection into the HPLC
system. The sample was analyzed on a Symmetry C18 (5 µm, 3.9 × 150 mm) column. The mobile phase
is composed by Water (A) and ACN (B), both containing 0.1% (v/v) formic acid and the composition
gradient was: an initial isocratic elution of 10% B for 2min, from 10 to 25% B in 8 min, from 25 to 90% B
in 5 min, 10% B until 3 min, followed by a re-equilibration step of 4 min. The flow rate was 1 mL/min
and the elution was performed at room temperature. The UV detection was fixed at 325 nm. Mass
spectra were generated in negative ion mode under constant instrumental conditions (ion spray voltage
5 kV, capillary voltage −12 V, capillary temperature 220 ◦C, and tube lens voltage −60 V). MS/MS data
were acquired in Dependent scan mode (Full-scan MS followed by MS/MS of the most intense ion).
HsFC (2.5 g) was dissolved in 50 mL of methanol and then subjected to a treatment with
PS-carbonate (5 g). The mixture was shaken at room temperature for 40 min, then filtered and washed
with methanol (30 mL) and dichloromethane (150 mL). The combined filtrates were evaporated
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under reduced pressure. The resin was then recovered and 50 mL of MeOH + 0.1% HCl was added.
The system was shaken for 1 h at room temperature, and the solvent filtered. The procedure was
performed twice. The combined methanolic filtrates were evaporated under reduced pressure and
then subjected to a flash chromatography on silica gel with 50% Toluene, 30% hexane, and 20%
isopropyl-alcohol as mobile phase. Six fractions were collected on the basis of the TLC profile. Fraction
2 (18 mg) corresponds to a single spot (TLC: MP = 5 Toluene: 3 hexane: 2 isopropyl-alcohol RF = 0.41).
It underwent Nuclear Magnetic Resonance (1H- and 13C-NMR) and Mass Spectral (MS) analysis and
it has been identified as dimethyl 3-hydroxy-5-oxotetrahydrofuran-2,3-dicarboxylate. All the spectra
are reported in supplementary material, Figure S2. ESI-MS: m/z 218 [M + H]+. 1H-NMR (CDCl3,
400 MHz): δH: 5.1 (1H, s), 3.9 (3H, s), 3.8 (3H, s), 3.0 (1H, d, J = 17.4 Hz), 2.8 (1H, d, J = 17.4 Hz).
13C-NMR (CDCl3): δC: 172, 168, 165, 82, 77, 55, 54, 40.
HsFC (5 g) was dissolved in 100 mL of methanol and then subjected to a treatment with
PS-carbonate (10 g). The mixture was shaken at room temperature for 40 min, then filtered and
washed with dichloromethane (300 mL). The filtrate was concentrated in vacuo and then subjected
to a flash chromatography on silica gel with 70% dichloromethane and 30% ethyl acetate as mobile
phase. Four fractions were collected on the basis of the TLC profile. The second fraction corresponds
to a pure compound (TLC: MP = 7 DCM: 3 AcOEt RF = 0.37; 9 mg) as a yellow oil. Its structure
was then incestigated with Nuclear Magnetic Resonance (1H- and 13C-NMR) and Mass Spectral (MS)
techniques and elucidated as 5-hydroxy-2H-pyran-6-carbaldehyde (see supplementary material S2).
ESI-MS: m/z 127 [M + H]+, 149 [M + Na]+. 1H-NMR (CDCl3, 400 MHz): δH: 9.6 (1H, s), 7.2 (1H, m),
6.4 (1H, m), 4.6 (2H, d).13C-NMR (CDCl3): δC: 178, 160, 155, 125, 110, 58.
4.5. Cell Culture
RPMI 8226 human multiple myeloma cells (ATCC, Manassas, VA, USA) were cultured in RPMI
1640 medium (Euroclone, Pero, Italy) supplemented with 10% fetal bovine serum (FBS), 1% glutamine,
1% Penicillin and Streptomycin (Euroclone, Pero, Italy). Cells were incubated at 37 ◦C and 5% CO2 in
a humidified incubator.
HsEE and HsFC were dissolved in phosphate-buffered saline (PBS) at 1 g/mL concentration and
then diluted directly into culture medium to working concentrations.
4.6. Biological Assays
4.6.1. MTT Assay
RPMI 8226 cells were seeded in 96-well plates at 10 × 103 cells/well density and were
treated with different concentrations of HsEE (1–50 mg/mL) and HsFC (1–10 mg/mL). Untreated
cells represented the controls. After 24, 48, and 72 h of treatment, a 5 mg/mL solution
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, St. Louis,
MO, USA) was added directly to culture medium, at final concentration of 0.5 mg/mL. After 4 h
of incubation at 37 ◦C, plates were centrifuged at 2 × 103 RPM and culture medium was removed,
formazan crystals were solubilized in acidified 2-propanol (HCl 0.3%), and absorbance was read at
560 nm in a microplate reader (BMG-Labtech, Offenburg, Germany).
4.6.2. Trypan Blue Vital Count
RPMI 8226 cells were seeded in six-well plates at 250 × 103 cells/well density and were treated
with different concentrations of HsFC. Untreated cells represented the controls. After 24, 48, and 72 h
of treatment cells were harvested and stained with Trypan blue vital dye (Sigma-Aldrich, USA). Viable
and dead cells were counted in a Burker hemocytometer under a light microscope (Eclipse TS100,
Nikon, Tokyo, Japan).
The reversibility of HsFC was evaluated by Trypan blue vital count. Cells were plated and treated
as previously described. After 24 h of treatment cells were harvested. Culture medium was removed
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after centrifugation at 1200 RPM and it was replaced with fresh medium without HsEE/HsFC. After 24,
48, and 72 h cells were stained and counted as previously described.
4.6.3. Boyden Chamber Assay
Boyden chamber assay was used to assess RPMI 8226 cell migration and invasion as previously
described [20]. Briefly, 5 × 103 RPMI 8226 cells were plated in HsEE/HsFC serum free medium in
the upper compartment of the Boyden chamber. Culture medium supplemented with 10% FBS as
chemo-attractant was placed in the lower compartment of the chamber. Compartments were separated
by a polycarbonate membrane with 8 µm pores (Biomap, Agrate Brianza, MB, Italy). The membrane
was coated with gelatin at 0.2 mg/mL concentration.
After 16 h of incubation at 37 ◦C, the membrane was removed, fixed with cold methanol,
and stained with Diff quick staining kit (Biomap, Agrate Brianza, MB, Italy). Cells on the lower surface
of the membrane were counted under a light microscope.
4.6.4. DRG Neurotoxicity Assay
All experimental procedures were approved by the Ethics Committee for Animal Studies of the
University of Milan Bicocca.
A pregnant Sprague Dawley rat (Envigo, Udine, Italy) was sacrificed after a deep anesthesia.
Embryos were collected in L15 medium (Euroclone, Pero, Italy) and DRG were removed after dissection.
DRGs were seeded in 35 mm dishes previously coated with collagen and filled with AN2 medium
(MEM (Euroclone, Pero, Italy), 10% Calf Bovine Serum (Euroclone, Pero, Italy), 1.4 mM L-Glutamine
(Euroclone, Pero, Italy), 0.6% Glucose (Sigma-Aldrich, USA), and 5 ng/mL Nerve Growth Factor (NGF)
(Thermo Fisher, Waltham, MA, USA). After 2 h, culture medium was removed and replaced with
treatment medium (HsEE 1–10 mg/mL or HsFC 1–5 mg/mL). Untreated DRG represented the controls.
After 24 and 48 h, micrographs of DRG were taken under a light microscope (Nikon Eclipse TS100)
and the length of DRGs neurites was measured with ImageJ software (National Institutes of Health,
Bethesda, MD, USA, http://imagej.nih.gov/ij).
4.7. Statistical Analysis
Data are reported as mean ± standard deviation (SD) from at least three independent experiments.
Statistical analysis was performed using GraphPad Prism 3 software. The differences between control
and treated cells were evaluated using One Way ANOVA analysis of variance followed by Dunnet’s
multiple comparison test. Statistical significance was set at p < 0.05 or p < 0.01.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/24/13/2500/s1.
Figure S1: HPLC-UV profile recorded of HsEE, HsF A, HsF B, HsF C and HsF. Table S1: Main peaks of HsEE and
HsF A-D. Figure S2: MS/MS spectrum m/z293 Hibiscus acid Hibiscus acid 6-methyl ester and Caffeic acid derived.
Figure S3: NMR spectra of Hib-ester. Figure S4: IR analysis of Hib-ester. Figure S5: MS analysis of Hib-ester.
Figure S6: NMR spectra of Hib-carbaldehyde. Figure S7: MS analysis of Hib- carbaldehyde. Figure S8: Neurite
outgrowth from DRG treated with Hib-ester and with Hib- carbaldehyde.
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